The launch of the Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology & Innovation) initiative in India signals a paradigm shift for the pharmaceutical sector. The initiative aims to transition India from its traditional role as a high-volume producer of small-molecule generics into a global powerhouse for high-value biologics and biosimilars. This strategic reorientation is driven by a domestic and global disease burden shifting toward non-communicable diseases such as cancer, diabetes, and autoimmune disorders, where advanced biologic therapies are essential for survival and quality of life. India has the potential to lead in Next-Generation Biopharmaceuticals (NGB) through Biopharma SHAKTI initiatives. However, it is important to understand biologics and address the related challenges. This document discusses the main opportunities, challenges, and possible solutions.
Why Biopharma over Small-Molecule Generics?
The fundamental scientific and industrial divergence between biopharmaceuticals and traditional generics rests on molecular complexity, manufacturing methodology, and regulatory scrutiny. Traditional generic drugs are small-molecule entities synthesised through precise, predictable chemical reactions. In contrast, biologics (biopharmaceuticals) are large, complex proteins derived from living organisms, such as bacteria, yeast, or mammalian cells.
While a generic aspirin molecule has a molecular weight of approximately 180 Daltons, a monoclonal antibody exceeds 150,000 Daltons. This massive size correlates to a hierarchical organisation of primary, secondary, tertiary, and quaternary protein structures that determine therapeutic efficacy.
In generics manufacturing, the end product can be chemically characterised as identical to the originator. However, because biologics are produced in living systems, they are inherently heterogeneous. Even within a single production batch, a biologic is a pool of protein populations rather than identical molecules. This variability is driven by Post-Translational Modifications, most notably glycosylation, the attachment of sugar molecules to the protein backbone. Glycosylation patterns are host-dependent and functionally determinative for the drug’s mechanism of action, stability, and immunogenicity.
| Feature | Small-Molecule Generics | Next-Generation Biopharmaceuticals (NGB) |
| Source | Chemical synthesis in the lab | Living cell cultures/bioreactors |
| Structure | Simple, well-defined, homogenous | Large, complex, heterogeneous |
| Molecular Weight | Less than 500 Daltons | >150,000 Daltons |
| Stability | Highly stable | Sensitive to light/temp; unstable |
| Immunogenicity | Generally non-immunogenic | High potential to trigger an immune response |
| Regulatory Path | Bioequivalence | Biosimilarity (comparability exercise) |
Advanced Production Strategies in Biomanufacturing
India is investing in state-of-the-art bioprocessing technologies that may optimise yield, flexibility, and compliance. At present, the industrial production of complex glycosylated proteins relies on mammalian expression systems, primarily Chinese Hamster Ovary cells. These cells are preferred for their genetic stability and ability to perform human-like Post-Translational Modifications.
In line with the Biopharma SHAKTI 2026 initiatives, the Indian biopharma sector will start using single-use bioreactors and disposable components. Unlike traditional stainless-steel plants, single-use bioreactors eliminate the need for complex cleaning-in-place and sterilisation-in-place protocols, drastically reducing the risk of batch-to-batch cross-contamination. This modularity allows facilities to pivot between different products with minimal downtime, which is critical for the discovery in India for the value strategy.
In addition, the industry will explore continuous biomanufacturing to support the global demand. The continuous systems will offer a smaller facility footprint, increased productivity, and superior product consistency by operating at a steady-state.
The regulatory framework under SHAKTI 2026 emphasises Quality by Design. Instead of relying solely on end-product testing, quality is “built-in” through the identification of Critical Quality Attributes and Critical Process Parameters. Process Analytical Technology tools, such as real-time Raman spectroscopy and mass spectrometry, are integrated into the production line to monitor these variables and maintain the process within a defined design space.
Strategic Pillars of Next-Generation Biopharmaceuticals in India
The central government’s investment will be directed through key structural reforms aimed at strengthening India’s global research credibility in Next-Generation Biopharmaceuticals (NGB).
- NIPER Modernisation: The establishment of 3 new and the upgradation of 7 existing National Institutes of Pharmaceutical Education and Research (NIPERs) creates a dedicated network for advanced biopharmaceutical sciences.
- Clinical Research Network: The creation of a large number of accredited clinical trial sites aims to address the historically fragmented trial landscape, providing a diversity of patient data necessary for the global validation of complex biosimilars.
- Regulatory Overhaul: Strengthening the Central Drugs Standard Control Organisation (CDSCO) with a dedicated scientific review cadre and specialists is intended to align India’s approval timelines with global benchmarks.
- Indigenous Raw Materials: Under the Biomanufacturing and Biofoundry pillar, India aims to reduce import dependence for critical reagents like chemically defined media and single-use bags, supporting a self-reliant “Atmanirbhar” ecosystem.
Technical Challenges and Strategic Solutions
| Challenge | Impact on the Biopharma Sector | Proposed Solution under SHAKTI 2026 |
| Capital Intensity | 50 x initial cost as compared to small-molecule generics | Investment in biopharma facilities for research and development to lower production costs. |
| Analytical Hurdles | Difficult to characterise complex biologics/Post-Translational Modifications | Investment in advanced mass spectrometry and analytical hubs at NIPERs |
| Supply Chain | Dependence on imported bioprocessing materials | Biofoundry initiative to promote domestic production of reagents/consumables |
| Cold Chain Spoilage | More than 20% of sensitive products may be damaged in transit | Adoption of AI-driven real-time IoT monitoring and route optimisation |
Conclusion
Biopharma SHAKTI 2026 is more than financial support. It is a strategic plan to move India from small-molecular generics to Next-Generation Biopharmaceuticals to enhance the value chain. By building strong expertise in biologics and biosimilars, and by adopting advanced manufacturing technologies such as single-use systems and continuous processing, India can benefit from the global patent cliff.
The program promotes innovation-driven research, strong clinical trial networks, and a science-based regulatory system. It will also create significant job opportunities in research, manufacturing, quality control, regulatory affairs, and clinical development.
This initiative will help India grow from the pharmacy of the world into a global innovation hub, delivering affordable and advanced healthcare solutions worldwide while generating skilled employment across the biotechnology sector.
